REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
04/10/2025
Voltar para busca
Dado oficial do USPTO
SMARTAG
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
05/10/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
18/06/2013
Data de registro
04/10/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/10/2023
Última transação
05/10/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
702
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
20/10/2014
Primeiro uso no comércio
20/10/2014
Código do desenho
4
Tipo de titular
03
Localização do titular
Somerset, NJ
Examinador
LEVINE,HOWARD B
Unidade examinadora
M60
Localização atual
TMO LAW OFFICE 115
Titulares e representantes
Titulares
CATALENT PHARMA SOLUTIONS, INC.
Representantes
Vanessa A. Ignacio, LOWENSTEIN SANDLER LLP
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemical and biological reagents in the nature of or used to create or improve antibody-drug conjugates or any protein conjugated to a drugpoly nucleotideanother proteinchemicalother functional entity used in industry and science; chemicals for use in bioconjugationreversible bioconjugationirreversible bioconjugationreversible cysteine protectionsurface modificationprodrug production for scientific use; biochemicalspolypeptidespolypeptides for in vivo applicationspolypeptides for in vitro applicationspolynucleic acidspolynucleic acids for in vivo applicationspolynucleic acids for in vitro applications for scientific use; biomoleculesproteinspeptidesantibodiesantibody fragmentsantibody mimetic proteinspolynucleic acids for scientific use; chemical products for diagnostic useconjugates of polypeptides with small molecule drugsimaging agentsflourocromes and radiolabels for medical research applications; biochemical preparationspolypeptidespolynucleic acidsantibodiesall for use in basic scientific research and developmentmedical research; diagnostic preparations for scientific or research use in connection with antibody drug conjugates; biochemical preparationspolypeptidespolynucleic acidsantibodiesall for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system
Classe 5
Pharmaceutical preparations for the prevention or treatment of human diseasesdiseases of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; chemicalbiological and biochemical preparations for medical and pharmaceutical purposesantibody-drug conjugates or any protein conjugated to a drugpoly nucleotideanother proteinchemicalother functional entity or such preparations used as linker or payload molecules therein used to treat cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; pharmaceutical preparationspolypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; biological preparationspolypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; diagnostic preparations for medical purposes in connection with the diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; antibody preparationsantibody or protein bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive systemincluding antibody/protein-drug conjugatesantibody/protein-radiolabled conjugates and antibody/protein-imaging agent conjugates; chemical products for medical diagnostic usepolypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system; biochemical preparationspolypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of cancer and diseases and disorders of the immune systemrespiratory systemcardiovascular systemdigestive systemendocrine systemlymphatic systemmuscular systemskeletal systemnervous systemurinary systemintegumentary system and reproductive system
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
25/12/2024
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
05/10/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
05/10/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/10/2023
E815
TEAS SECTION 8 & 15 RECEIVED
04/04/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/10/2021
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
22/05/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
04/10/2016
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
31/08/2016
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
30/08/2016
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/08/2016
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/08/2016
IUAF
USE AMENDMENT FILED
13/07/2016
EISU
TEAS STATEMENT OF USE RECEIVED
13/07/2016
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
19/01/2016
EX1G
SOU EXTENSION 1 GRANTED
15/01/2016
EXT1
SOU EXTENSION 1 FILED
15/01/2016
EEXT
SOU TEAS EXTENSION RECEIVED
15/01/2016
PCGR
PETITION TO DIRECTOR GRANTED
02/09/2015
APET
ASSIGNED TO PETITION STAFF
31/08/2015
TPDR
TEAS PETITION TO DIRECTOR RECEIVED
04/08/2015
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
28/07/2015
CHPN
POST PUBLICATION AMENDMENT – NOT ENTERED
25/07/2015
APET
ASSIGNED TO PETITION STAFF
22/07/2015
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
16/07/2015
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
16/06/2015
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
23/12/2014
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/12/2014
PUBO
PUBLISHED FOR OPPOSITION
02/12/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/11/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
28/10/2014
ALIE
ASSIGNED TO LIE
28/10/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/10/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/09/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/09/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/09/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/04/2014
GNRT
NON-FINAL ACTION E-MAILED
02/04/2014
CNRT
NON-FINAL ACTION WRITTEN
02/04/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/03/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/03/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/03/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
16/09/2013
GNRT
NON-FINAL ACTION E-MAILED
16/09/2013
CNRT
NON-FINAL ACTION WRITTEN
16/09/2013
DOCK
ASSIGNED TO EXAMINER
10/09/2013
MPMK
NOTICE OF PSEUDO MARK E-MAILED
28/06/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
27/06/2013
NWAP
NEW APPLICATION ENTERED
21/06/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SMARTAG ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.